Ethics in the private sector: the moral dilemmas behind corporate case studies

Ethics does not end at the company gate. A pharmaceutical firm, a factory, a bank: their choices touch millions of lives, move markets, and scar or heal communities. Business ethics asks what is right and wrong in commercial life, and this article turns its core ideas into a working method for the private-sector case studies of GS-4.

Why private-sector ethics matters for governance

When a company falsifies safety data, it is not only a market event: patients, workers and rivers bear it. Governance is the quality of power wherever power sits, and private power now sits on balance sheets that rival state budgets. Ethics in business is therefore a governance question, not a management elective: the same values of integrity, accountability and public interest apply, only the stage changes.

Business ethics is the branch of applied ethics that asks what is right and wrong in commercial life: how firms should treat workers, customers, investors, communities and the environment, and how individuals inside firms should decide when these duties collide with profit. It matters for UPSC because nearly every second GS-4 case study is set in a company, and the examiner tests whether you can reason about private power with public values.

Shareholder vs stakeholder: the two lenses of corporate duty

Shareholder primacy is the doctrine, most associated with economist Milton Friedman, that a corporation's only social responsibility is to maximise profits for its owners within the rules of the game. In this lens the manager is the servant of one master, the shareholder, and every other claim is a cost to be minimised. It is a coherent ethic, but it has no answer when the cost being minimised is a human life.

Stakeholder theory, formulated by R. Edward Freeman in 1984, holds that a company should be run for the benefit of all its stakeholders, everyone who affects or is affected by its actions, not only its owners. The moral logic is simple: those who bear a company's risks deserve a voice in its decisions. Indian company law itself leans this way, through mandatory CSR and board duties to the community.

• Shareholders: owners who risk capital and expect returns.
• Employees: who risk their livelihoods, health and time.
• Customers: who trust the product with their safety and money.
• Communities and the environment: who absorb the firm's pollution, displacement and noise.
• The state: which grants the licence to operate and enforces the rules.

Carroll's pyramid of corporate responsibility is a four-layer model of what society expects from business: be profitable (economic), obey the law (legal), act rightly (ethical), and give back (philanthropic). In answers, test a company's conduct layer by layer: a profitable, law-abiding firm can still fail the ethical layer, and that failure is exactly what case studies probe.

Fiduciary duty and the principal-agent problem

Fiduciary duty is the obligation of a person entrusted with another's interests, a trustee, director or manager, to act solely for that principal's benefit, with loyalty, care and good faith. It is the strictest duty the law knows. Loyalty forbids self-dealing, care demands diligence, and obedience requires following lawful instructions. A CEO who diverts company funds to a relative's firm breaches all three at once.

The principal-agent problem is the conflict that arises when the agent who decides does not fully bear the consequences, which fall instead on the principal. Because the manager's interests, salary, status, survival, differ from the owners' or the public's, the agent may quietly act for himself. Corporate cases are therefore never only about greedy individuals; the structure itself invites the wrongdoing.

Moral hazard is the tendency of a person shielded from the consequences of risk to take greater risks. A manager paid for short-term profit with no clawback faces moral hazard: he gambles with other people's money and keeps the winnings. In answers, name the hazard first, then propose structural fixes rather than mere sermons.

• Disclose everything material: sunlight removes the shadows where agents hide.
• Align incentives: clawbacks, deferred bonuses and long vesting make the agent feel the consequences.
• Independent oversight: audit committees and independent directors who owe the agent nothing.
• Rotate key roles: procurement, treasury and audit chairs should never become personal fiefdoms.

Conflict of interest: serving two masters

A conflict of interest is a situation in which a person's private interests, or duties to another party, could improperly influence their professional judgment. The test is appearance, not only actual corruption: if a reasonable person would doubt your impartiality, the conflict exists and must be declared. Waiting until the bias shows is already a failure.

Related-party transactions are deals between a company and entities linked to its own directors or promoters. Insider trading is trading in a company's securities using material information not available to the public. Both are conflict-of-interest archetypes: private advantage extracted from a position of trust, and both recur in GS-4 corporate cases.

Recuse, disclose, divest: the three verbs of handling conflicts. A manager who cannot decide impartially must step aside from the decision (recuse), declare the interest openly (disclose), or remove the interest entirely (divest). Memorise the trio; it resolves half the conflict questions in one line.

Indian public life offers a clean illustration of recusal done right. When Arun Jaitley, as a minister, stepped away from handling the Vodafone tax matter because he had earlier served as the company’s adviser, he applied the appearance test: not whether he would actually favour a former client, but whether a reasonable citizen could doubt his impartiality. Recusal before the decision is what separates ethics from damage control.

Whistleblowing: loyalty to the organisation vs loyalty to the truth

Whistleblowing is the act of disclosing, inside or outside an organisation, information about wrongdoing, danger or illegality that the organisation is concealing or ignoring. It is loyalty to the public interest breaking ranks with loyalty to the employer, which is why it feels like betrayal even when it is duty.

• Internal whistleblowing: reporting to the audit committee, ethics officer or board, the first and preferred channel.
• External whistleblowing: approaching the regulator or the press, justified only when internal channels fail or harm is imminent.
• Justified whistleblowing needs four conditions: credible evidence of serious harm, internal remedies tried first, disclosure proportionate to the harm, and a motive of public interest rather than revenge.

Indian company law requires large companies to run vigil mechanisms for directors and employees, and SEBI's listing norms extend the shield. But law protects the channel; only conscience walks through it. Examiners reward answers that protect the whistleblower and preserve due process for the accused in the same breath.

The ethics of whistleblowing is genuinely contested, which is why examiners reward answers that weigh both sides before taking a stand. The ledger:

Corporate conscience: can a company have a moral character?

Corporate conscience is the idea that a company, though a legal fiction, can develop a stable moral character through its culture, codes and the habits of its people. Just as a person of character does right reflexively, an ethical company makes decent choices even when no regulator is watching. It is what separates compliance, doing right because you are checked, from integrity, doing right because it is right.

Culture is the real code. Written policies are paper; what gets rewarded, who gets promoted, and what the boss laughs at, that is the company's conscience in action. This is why case studies keep asking about the CEO's tone at the top: ethical leadership is leadership that models values personally and enforces them without exception.

Worked mini-dilemmas in case-study style

Read each dilemma as the examiner wrote it, then apply the method from the case-study framework article: name the decision-maker, map the stakeholders, list the options with honest merits and demerits, and commit to a course of action. The recommended approach is a model answer, not a gospel: what earns marks is the reasoning, not the conclusion.

Dilemma 1: the pharma quality head and the contaminated batch

You are the head of quality control at a mid-sized pharmaceutical company. A routine test finds bacterial contamination in a batch of injectable antibiotics worth several crores, already packed for dispatch to government hospitals. Your CEO asks you to retest selectively until it passes, reminding you that a full recall will bankrupt the company and cost 400 jobs. The trucks leave tonight.

• You: professional duty, your licence, and your conscience.
• Patients: who will receive the injections, the most vulnerable party.
• The company and its 400 workers: livelihoods that depend on survival.
• The CEO: who is asking you to bend the science.
• The regulator and public trust: in medicines and in the industry.

• Option A: retest selectively and release. Merit: saves the company and 400 jobs. Demerit: risks patient deaths, professional misconduct and criminal liability; one tragedy ends the company anyway.
• Option B: refuse and go straight to the press. Merit: protects patients immediately. Demerit: skips internal remedy, destroys colleagues' livelihoods without due process, and looks like sabotage.
• Option C: halt dispatch, order a full supervised retest, destroy the batch if confirmed, report to the regulator yourself, and place a survival plan before the board. Merit: protects patients, keeps the legal process clean, preserves your integrity. Demerit: the company may still fail.

Recommended approach: choose C. Patient safety is non-negotiable: the deontological duty not to harm overrides the consequentialist arithmetic of jobs, and your fiduciary duty to the public through drug-safety law outranks loyalty to the CEO. The disclosure is internal-first, to the board and regulator, not press-first, because due process protects innocent colleagues while the patients are protected by the halt.

Dilemma 2: the HR manager and the contract worker's death

You are the HR head at a manufacturing plant. A contract worker dies in a machinery accident. The contractor, a politically connected firm, pressures you to record it as a road accident outside the premises, so the company avoids compensation liability and a safety audit. The worker's widow, who cannot read, has come to you with the death certificate.

• You: integrity against pressure from a powerful contractor.
• The widow and her children: entitled to statutory compensation, unable to fight for it.
• The contractor: seeking to erase its liability.
• The company: short-term cost versus long-term trust and legal exposure.
• Permanent workers: watching how the firm treats its dead.

• Option A: falsify the record. Merit: avoids immediate liability. Demerit: fraud, denies the family its legal due, and corrodes every safety log after it.
• Option B: record truthfully, trigger statutory compensation and a full safety audit, and personally ensure the widow's claim is filed. Merit: justice, legal compliance, and the workforce's lasting trust. Demerit: short-term cost and the contractor's retaliation.
• Option C: record truthfully but settle with the widow below her entitlement. Merit: none, ethically. Demerit: compounds the wrong with exploitation of her illiteracy.

Recommended approach: choose B. Compensation law exists precisely because the dead cannot bargain; your fiduciary duty as HR head runs to the workforce, not to the contractor. A company that falsifies one death will falsify every safety log that follows, and the workers know it.

Dilemma 3: the CEO and the bribe for a licence

You are the CEO of a logistics company. A state official demands a personal payment to clear an operating licence your trucks need within a week; without it, two thousand employees face unpaid leave. Your board chair hints that everyone pays and the amount is small.

• You: the decision and the personal risk.
• Employees and their families: two thousand livelihoods in the balance.
• Shareholders: who want the licence, lawfully.
• The official and the system: one bribe feeds the whole machinery of extortion.
• Honest competitors: who refuse to pay and lose business for it.

• Option A: pay the bribe. Merit: immediate relief. Demerit: illegal, entrenches extortion, and exposes the company to permanent blackmail.
• Option B: refuse and shut operations. Merit: clean hands. Demerit: punishes innocent employees for your virtue.
• Option C: refuse the bribe, document the demand, escalate through the anti-corruption channel, seek interim legal relief, and communicate honestly with employees about the delay. Merit: lawful, breaks the extortion cycle, protects the firm long term. Demerit: painful in the short term.

Recommended approach: choose C. Bribery is a deontological wrong: paying once makes the company a permanent payer and corrupts the market for every honest competitor. The courage lies in refusing while shielding employees through transparency and legal remedies, not in sacrificing them to keep your own conscience clean.

Dilemma 4: the sustainability manager asked to greenwash ESG data

You are the sustainability head of a listed cement company. The CFO asks you to reclassify routine maintenance spending as green investment and understate emissions in the BRSR disclosure, so the company keeps its ESG rating and index inclusion. Your annual bonus depends on that rating.

• You: bonus and career against professional integrity.
• Investors: relying on the disclosure to allocate crores.
• The public: breathing the actual emissions.
• The regulator: SEBI, which mandates truthful BRSR reporting.
• Genuine green companies: undercut by the lie.

• Option A: comply and keep the rating. Merit: bonus, index inclusion. Demerit: fraud on investors, classic greenwashing, personal liability when discovered.
• Option B: resign quietly. Merit: personal integrity intact. Demerit: the fraud continues and no one is warned; it is moral evasion.
• Option C: refuse, record your objections in writing, escalate to the audit committee and board, and if overruled, report through the vigil mechanism to the regulator. Merit: protects investors, follows the lawful channel, creates a paper trail. Demerit: real career risk.

Recommended approach: choose C. ESG disclosure is a fiduciary act toward investors; falsifying it misleads the market as surely as cooking the books. Quiet resignation saves your conscience while abandoning the victims. Record, escalate, and only then go external: the order matters as much as the refusal.

Key Terms

• Business ethics: Business ethics is the branch of applied ethics that judges right and wrong in commercial life: how firms should treat workers, customers, investors, communities and the environment, and how individuals inside firms should decide when these duties collide with profit.
• Shareholder primacy: Shareholder primacy is the doctrine, associated with Milton Friedman, that a corporation's only social responsibility is to maximise returns to its owners within the rules of the game. Stakeholder theory stands directly against it.
• Stakeholder theory: Stakeholder theory, formulated by R. Edward Freeman in 1984, holds that a company should be governed for the benefit of all its stakeholders, everyone who affects or is affected by its actions, not only its shareholders.
• R. Edward Freeman: R. Edward Freeman is the management scholar who formulated stakeholder theory in 1984. His core claim, that those who bear a company's risks deserve a voice in its decisions, underpins modern CSR and ESG thinking.
• Carroll's pyramid: Carroll's pyramid of corporate responsibility is Archie Carroll's four-layer model of business duties: be profitable (economic), obey the law (legal), act rightly (ethical), and give back (philanthropic). A useful ladder for testing conduct in case studies.
• Fiduciary duty: Fiduciary duty is the obligation of a person entrusted with another's interests to act solely for that principal's benefit, with loyalty, care and good faith. It binds trustees, directors and managers, and it is the strictest duty the law knows.
• Principal-agent problem: The principal-agent problem is the conflict that arises when the agent who decides does not bear the consequences, which fall on the principal. Divergent interests then push the agent to serve himself, which is why corporate governance needs structural checks, not just good intentions.
• Moral hazard: Moral hazard is the tendency of a person shielded from the consequences of risk to take greater risks. A manager rewarded for short-term profit with no clawback gambles with other people's money: the classic corporate case-study trap.
• Conflict of interest: A conflict of interest is a situation in which a person's private interests, or duties to another party, could improperly influence their professional judgment. The test is appearance as well as reality, and the remedies are recuse, disclose and divest.
• Insider trading: Insider trading is buying or selling a company's securities using material information not available to the public. It is a conflict-of-interest archetype: private profit extracted from a position of trust, and it is prohibited under SEBI regulations.
• Related-party transaction: A related-party transaction is a deal between a company and an entity linked to its own directors or promoters. Such deals must be disclosed and approved at arm's length, because they are the classic channel for siphoning company wealth.
• Whistleblowing: Whistleblowing is the disclosure, inside or outside an organisation, of concealed wrongdoing, danger or illegality. Internal channels come first; external disclosure is justified when they fail and serious harm is imminent, with motive in the public interest.
• Corporate conscience: Corporate conscience is the idea that a company can develop a stable moral character through its culture, codes and habits. It separates compliance, doing right because you are checked, from integrity, doing right because it is right.
• Greenwashing: Greenwashing is the practice of making false or exaggerated claims about the environmental benefits of a product or company. In India, SEBI's BRSR framework for the top listed companies is the regulatory answer to it.

The prescription and the pitch: ethics of the pharma-doctor nexus

Few private-sector ethical failures touch citizens as directly as the commerce between pharmaceutical companies and doctors. The Supreme Court, hearing a public-interest plea, condemned the industry's practice of showering doctors with freebies, observing that the cost of these inducements is ultimately borne by patients in the price of medicines. In the case that made headlines, the maker of the widely used Dolo-650 was reported to have distributed around Rs 1,000 crore in incentives to doctors for prescribing its brands.

The ethical anatomy is straightforward. Prescriptions driven by incentives rather than patient need violate the doctor's fiduciary duty to the patient; patients pay twice, once in money and once in the risk of unnecessary medication; and the deals are struck in secrecy, beyond any scrutiny. Indian Medical Council regulations prohibit doctors from accepting gifts, travel facilities or cash from pharmaceutical companies, with violations punishable by removal from the medical registers. The Uniform Code of Pharmaceutical Marketing Practices (UCPMP) sets the industry's own ethical standard for drug promotion, restraining inducements and misleading claims.

The deeper frame is medical ethics' four principles. Beneficence is the duty to act for the patient's good. Non-maleficence is the duty to do no harm first. Autonomy is respect for the patient's right to make informed decisions about their own body. Justice is the fair distribution of care and its costs. A prescription written for the incentive fails all four, which is why the pharma-doctor nexus is not a marketing excess but a moral one.

The scale of the spending explains the persistence. One study found seven major pharmaceutical companies spending a total of about Rs 34,187 crore on marketing over eight years, a bill ultimately folded into the price of medicines. When promotion budgets dwarf research integrity, the prescription pad becomes a sales channel, and the patient pays twice: once in the drug’s price, once in the distortion of medical judgment.

Marketplace misconduct: cartels, cooked books and unsafe products

Beyond the boardroom, private-sector ethics fails in the marketplace in recurring patterns, each worth naming.

• Cartelisation and market manipulation: competitors colluding to fix prices or rig markets rather than competing, as when commission agents (arhatiyas) manipulate prices in agricultural produce market committee (APMC) mandis, or when insiders trade on non-public information. The victim is the price mechanism itself.
• Audit integrity: the auditor paid by the audited faces a standing conflict of interest; when auditors collude rather than question, frauds run for years before surfacing. The Yes Bank collapse, detailed in the corporate-governance article, is the textbook Indian case.
• Excessive competition: rivalry so intense that winning seems to require cheating, normalising manipulation as strategy rather than aberration.
• Profit at any ethical cost: firms shifting production to jurisdictions with weak labour and environmental laws, arbitraging human dignity across borders.
• Employee welfare traded away: startups choosing output over people, treating work-life balance as a luxury the mission cannot afford.
• Product safety sacrificed: rushing a drug or device to market before adequate safety testing, gambling with strangers' bodies for first-mover advantage.

The common thread is externalised cost: each pattern pushes harm onto farmers, investors, workers, patients or the public while privatising the gain. Private-sector ethics is, at bottom, the discipline of refusing that trade.

Mains case-study drill

You are the procurement manager of a public-sector-adjacent infrastructure company. A vendor hints that your child's school admission, currently stuck on a waiting list, can be arranged if his firm wins the upcoming equipment tender. The tender committee looks to you for the technical evaluation.

• Question 1: Identify the conflict of interest and explain why even the appearance of bias matters here.
• Question 2: Lay out your course of action, from immediate refusal to the systemic safeguards you would recommend.

Framing hint: a conflict-of-interest archetype testing recuse, disclose and divest; the admission is the private interest, the tender is the public trust.

You are a bank branch manager. Your regional head, who controls your promotion, pressures you to approve a large loan to a business group that has defaulted twice before, assuring you verbally that head office will regularise it later. The credit file does not support the loan.

• Question 1: Map the stakeholders and name the principal-agent problem at work.
• Question 2: What do you do when the order is verbal, the pressure is real, and the file is weak?

Framing hint: fiduciary duty to depositors versus obedience to a superior; verbal orders leave no trail, so create one.

You are a food-safety officer inspecting a packaged-foods factory owned by your former mentor, the teacher who funded your first year of college. You find serious hygiene violations that legally require a closure notice, which would bankrupt his unit.

• Question 1: Is this a conflict of interest even though the mentor never asked for a favour?
• Question 2: Resolve the clash between gratitude and duty, and state what you would actually do on the inspection floor.

Framing hint: gratitude is a virtue but not a licence; public health is a non-negotiable deontological duty.

You are the co-founder of a young startup. Your partner wants to copy a competitor's patented manufacturing process, arguing that enforcement is weak, the patent will expire soon, and the company's survival depends on cutting costs now.

• Question 1: Analyse the proposal through shareholder primacy and stakeholder theory.
• Question 2: What lawful alternatives would you place before the board instead?

Framing hint: tests whether survival justifies theft; corporate conscience is built exactly in such early choices.

You are the CSR head of a large company. The promoter asks you to route this year's CSR funds to a school run by his family trust, with invoices inflated to absorb the full budget. He reminds you that he appointed you and that the school does genuine charity work.

• Question 1: Identify the ethical issues, including the related-party dimension.
• Question 2: Draft your response to the promoter and the safeguards you would put in the CSR policy.

Framing hint: related-party routing of CSR funds; genuine charity does not launder inflated invoices.

You are a mutual fund manager. A senior colleague asks you to execute the fund's large buy orders after first placing his personal trades in the same stocks, sharing the tip as a favour for your silence about his earlier expense fiddling.

• Question 1: Name the violations involved and the fiduciary duties breached.
• Question 2: You need the colleague's goodwill for your career. What is your course of action?

Framing hint: front-running plus a loyalty trap; fiduciary duty to unit-holders admits no private bargains.

You are the marketing head of a pharmaceutical company. The new incentive scheme rewards your sales representatives on the value of prescriptions written by the doctors they manage. A senior doctor hints that a sponsored foreign conference trip would help his prescribing choices.

• Question 1: Identify the ethical violations: the doctor's fiduciary duty, the UCPMP's restraints, and the cost passed to patients.
• Question 2: Lay out your course of action, from redesigning the incentive scheme to the disclosures and safeguards you would institute.

Framing hint: Aligns with the GS-IV mains bank's recurring themes on private-sector ethics, conflict of interest and fiduciary duty; treat coaching-attributed PYQ years as themes only, never as citations.